Multiple Myeloma in Relapse Not Yet Recruiting Phase 2 / 3 Trials for Rivaroxaban (DB06228)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Not Yet Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03428373ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.Treatment